AppHatchery · sande11 · Mar 17, 2026 · Mar 20, 2026
diff --git a/.idea/deploymentTargetSelector.xml b/.idea/deploymentTargetSelector.xml
diff --git a/app/build.gradle b/app/build.gradle
@@ -33,8 +33,13 @@ android {
     }
 
     buildTypes {
+        debug {
+            buildConfigField "String", "DYNAMIC_LINK_DOMAIN", '"https://gatbreferenceguide.page.link"'
+        }
+
         release {
             minifyEnabled false
+            buildConfigField "String", "DYNAMIC_LINK_DOMAIN", '"https://apphatcherygatbreferenceguide.page.link"'
             proguardFiles getDefaultProguardFile('proguard-android-optimize.txt'), 'proguard-rules.pro'
             signingConfig signingConfigs.debug
             ndk {

diff --git a/app/src/main/assets/assets/style.css b/app/src/main/assets/assets/style.css
@@ -239,6 +239,10 @@ img {
   margin-bottom: 16px;
 }
 
+.header-title > div {
+  flex: 0 0 auto;
+}
+
 .last-updated {
   color: var(--last-updated-color);
   font-size: 15px;
@@ -437,7 +441,7 @@ td.uk-text-truncate {
   max-width: 0;
 }
 .uk-text-wrap {
-  white-space: wrap;
+  white-space: wrap !important;
 }
 
 /* End of import from UIkit.css file */
@@ -499,6 +503,15 @@ a {
   color: var(--body-color-secondary);
 }
 
+.tab-content .uk-table {
+  table-layout: fixed;
+  width: 100%;
+}
+
+/* .tab-content .uk-table th.uk-text-wrap {
+  width: 32%;
+} */
+
 /* Tabs */
 
 .uk-tabs-container .tabs {
@@ -581,7 +594,7 @@ td {
 }
 
 td {
-  animation: slideInBottom var(--transition-duration) ease-in-out forwards;
+  animation: slideInBottom var(--transition-duration) ease-in-out;
 }
 
 td ul {
@@ -716,13 +729,13 @@ h3.highlight {
   justify-content: center;
   align-items: center;
   font-family: serif;
-  font-size: 0.7rem;
+  font-size: 0.8rem;
   background-color: var(--primary-color);
   color: white;
   border-radius: 50%;
   cursor: pointer;
-  width: 18px;
-  height: 18px;
+  width: 16px;
+  height: 16px;
   line-height: 16px;
   margin: 0 0rem;
   position: relative;
@@ -757,16 +770,19 @@ h3.highlight {
 /* Tooltip positioning variants */
 .tooltip-right {
   left: 0px;
+  z-index: 5000 !important;
 }
 
 .tooltip-center {
   left: 50%;
   transform: translateX(-50%);
+  z-index: 5000 !important;
 }
 
 .tooltip-left {
   right: 0px;
   left: auto;
+  z-index: 5000 !important;
 }
 
 .tooltip-bottom-center {
@@ -776,13 +792,15 @@ h3.highlight {
   transform: translateX(-50%);
   margin-bottom: 0;
   margin-top: 10px;
+  z-index: 5000 !important;
 }
 
 .tooltip-center-center {
   bottom: -500px;
   left: 30%;
   margin-bottom: 0;
   margin-top: 10px;
+  z-index: 5000 !important;
 }
 
 /* Tooltip arrow */
@@ -802,6 +820,7 @@ h3.highlight {
   visibility: visible;
   opacity: 1;
   overflow: scroll;
+  z-index: 5000 !important;
 }
 
 /* Responsive table
@@ -867,15 +886,3 @@ h3.highlight {
     grid-template-columns: repeat(2, 1fr);
   }
 }
-
-/* Shift the long AAP isoniazid tooltip in the LTBI table slightly right
-  so its content is not clipped. Targets only this tooltip on table_5
-  and does not affect other tooltips.
-  This was done to solve the problem on the tooltip that was causing the text to be blurred by the background.
-   so the possitioning of the tooltip was changed to the left and the css below was added so that the pop up doesnt get clipped by the margin
-  */
-#table_5_dosages_for_recommended_lbti_treatment_regimens
-  .info-icon[data-tooltip*="American Academy of Pediatrics recommends an isoniazid dosage of 10 - 15 mg/kg"]
-  .tooltip {
-  right: -30px; /* move popup 30px to the right */
-}
diff --git a/app/src/main/assets/json/chapter.json b/app/src/main/assets/json/chapter.json
@@ -46,7 +46,7 @@
   },
   {
     "chapterId": 10,
-    "chapterTitle": "TB Infection Control: Hospital Isolation Procedures",
+    "chapterTitle": "TB Infection Prevention and Control in Healthcare Facilities",
     "chapterHomePosition": 0
   },
   {
@@ -56,7 +56,7 @@
   },
   {
     "chapterId": 12,
-    "chapterTitle": "Alternative Housing Program for Homeless TB Patients in Georgia",
+    "chapterTitle": "Alternative Housing Program for Persons with TB Experiencing Homelessness in Georgia ",
     "chapterHomePosition": 0
   },
   {

diff --git a/app/src/main/assets/json/chart.json b/app/src/main/assets/json/chart.json
@@ -59,7 +59,7 @@
     "id": "table_9_pediatric_dosage_isoniazid_in_children_(birth_to_15_years)",
     "subChapterTitle": "Special Clinical Situations",
     "subChapterId": 24,
-    "chartTitle": "Table 9: Pediatric dosage - isoniazid in children (birth to 15 years)",
+    "chartTitle": "Table 9: Pediatric Dosage in Children ( birth to 15 years)",
     "chartHomePosition": 0
   },
   {
@@ -124,5 +124,12 @@
     "subChapterId": 32,
     "chartTitle": "Table 18: Grady Hospital TB Isolation Policy",
     "chartHomePosition": 0
+  },
+  {
+    "id": "fig1_factors_to_be_considered",
+    "subChapterTitle": "Considerations",
+    "subChapterId": 22,
+    "chartTitle": "Figure 1: Factors to be considered in deciding to initiate treatment empirically for active tuberculosis (TB) (prior to microbiologic confirmation)",
+    "chartHomePosition": 0
   }
 ]
diff --git a/app/src/main/assets/pages/10_tb_infection_control_hospital_isolation_procedures.html b/app/src/main/assets/pages/10_tb_infection_control_hospital_isolation_procedures.html
@@ -21,15 +21,15 @@
                 <div>
                     <img src="../assets/ic_chapter.svg" width="16" height="16" class="ic_chapter_icon">
                 </div>
-                <p class="chapter-title">X. TB Infection Control: Hospital Isolation Procedures</p>
+                <p class="chapter-title">X. TB Infection Prevention and Control in Healthcare Facilities</p>
             </div>
             <p class="last-updated"><i>Last Updated October 2025</i></p>
         </div>
         <hr>
     </div>
 
     <p class="uk-paragraph">
-        Effective infection control efforts are essential in preventing nosocomial transmission of
+        Effective infection prevention and control efforts are essential in preventing nosocomial transmission of
         TB. A hierarchy of
         control measures is recommended to prevent TB transmission in health care facilities.</p>
     <ul class="uk-list uk-list-disc">

diff --git a/...es/10_tb_infection_control_hospital_isolation_procedures__a__administrative_controls.html b/...es/10_tb_infection_control_hospital_isolation_procedures__a__administrative_controls.html
@@ -21,7 +21,7 @@
                 <div>
                     <img src="../assets/ic_chapter.svg" width="16" height="16" class="ic_chapter_icon">
                 </div>
-                <p class="chapter-title">X. TB Infection Control: Hospital Isolation Procedures</p>
+                <p class="chapter-title">X. TB Infection Prevention and Control in Healthcare Facilities</p>
             </div>
             <p class="last-updated"><i>Last Updated October 2025</i></p>
         </div>
@@ -39,7 +39,7 @@
     <p class="uk-paragraph">
         Grady Memorial Hospital in Atlanta has prevented nosocomial transmission in large part by the effective use of
         administrative controls. Careful screening of patients and isolation of those at risk for TB have been
-        accomplished by the introduction of an expanded respiratory isolation policy.</p>
+        accomplished by the introduction of an expanded respiratory isolation policy (Airborne Infection Isolation Precautions).</p>
 </div>
 </body>
 

diff --git a/...ction_control_hospital_isolation_procedures__b__surveillance_for_health_care_workers.html b/...ction_control_hospital_isolation_procedures__b__surveillance_for_health_care_workers.html
@@ -20,7 +20,7 @@
                 <div>
                     <img src="../assets/ic_chapter.svg" width="16" height="16" class="ic_chapter_icon">
                 </div>
-                <p class="chapter-title">X. TB Infection Control: Hospital Isolation Procedures</p>
+                <p class="chapter-title">X. TB Infection Prevention and Control in Healthcare Facilities</p>
             </div>
             <p class="last-updated"><i>Last Updated October 2025</i></p>
         </div>
@@ -29,7 +29,7 @@
 
     <p class="uk-paragraph">
         In general, the risk of occupational acquisition of TB is low among the large majority of US health care workers
-        (HCWs) given the changing epidemiology of the disease in the U.S. </p>
+        (HCWs) given the current epidemiology of the disease in the U.S. </p>
     <p class="uk-paragraph">
         The risk of TB exposure among most US-based health care workers (HCWs) is similar to the general population given the decreased TB incidence and improved hospital infection prevention and control measures in the U.S.
     </p>
@@ -51,7 +51,7 @@
     <p class="uk-paragraph">
         Any worker who develops symptoms of active TB disease or whose test for LTBI (TST or IGRA) converts to positive
         should be evaluated promptly. Health care workers with recent TB infection on the basis of a conversion to a
-        positive test for LTBI (regardless of age) and no evidence of active disease should be encouraged to take
+        positive test for LTBI (regardless of age) and no evidence of active TB disease should be encouraged to take
         treatment for LTBI (see <a href="3_treatment_of_latent_tb_infection_(ltbi).html"> Treatment for LTBI</a>).</p>
 
     <div id="table_19_grady_hospital_tb_isolation_policy" class="uk-overflow-auto">

diff --git a/...ges/10_tb_infection_control_hospital_isolation_procedures__c__environmental_controls.html b/...ges/10_tb_infection_control_hospital_isolation_procedures__c__environmental_controls.html
@@ -20,7 +20,7 @@
                 <div>
                     <img src="../assets/ic_chapter.svg" width="16" height="16" class="ic_chapter_icon">
                 </div>
-                <p class="chapter-title">X. TB Infection Control: Hospital Isolation Procedures</p>
+                <p class="chapter-title">X. TB Infection Prevention and Control in Healthcare Facilities</p>
             </div>
             <p class="last-updated"><i>Last Updated October 2025</i></p>
         </div>

diff --git a/..._infection_control_hospital_isolation_procedures__d__personal_respiratory_protection.html b/..._infection_control_hospital_isolation_procedures__d__personal_respiratory_protection.html
@@ -20,7 +20,7 @@
                 <div>
                     <img src="../assets/ic_chapter.svg" width="16" height="16" class="ic_chapter_icon">
                 </div>
-                <p class="chapter-title">X. TB Infection Control: Hospital Isolation Procedures</p>
+                <p class="chapter-title">X. TB Infection Prevention and Control in Healthcare Facilities</p>
             </div>
             <p class="last-updated"><i>Last Updated October 2025</i></p>
         </div>

diff --git a/app/src/main/assets/pages/11_community_tuberculosis_control.html b/app/src/main/assets/pages/11_community_tuberculosis_control.html
@@ -20,7 +20,7 @@
                 <div>
                     <img src="../assets/ic_chapter.svg" width="16" height="16" class="ic_chapter_icon">
                 </div>
-                <p class="chapter-title">XI. Community Tuberculosis Control</p>
+                <p class="chapter-title">XI. Community Tuberculosis Prevention Control </p>
             </div>
             <p class="last-updated"><i>Last Updated October 2025</i></p>
         </div>

diff --git a/...c/main/assets/pages/11_community_tuberculosis_control__a__tb_surveillance_in_georgia.html b/...c/main/assets/pages/11_community_tuberculosis_control__a__tb_surveillance_in_georgia.html
@@ -21,7 +21,7 @@
                 <div>
                     <img src="../assets/ic_chapter.svg" width="16" height="16" class="ic_chapter_icon">
                 </div>
-                <p class="chapter-title">XI. Community Tuberculosis Control</p>
+                <p class="chapter-title">XI. Community Tuberculosis Prevention Control </p>
             </div>
             <p class="last-updated"><i>Last Updated October 2025</i></p>
         </div>

diff --git a/...pages/11_community_tuberculosis_control__b__how_to_report_tb_as_a_notifiable_disease.html b/...pages/11_community_tuberculosis_control__b__how_to_report_tb_as_a_notifiable_disease.html
@@ -21,7 +21,7 @@
             <div>
                 <img src="../assets/ic_chapter.svg" width="16" height="16" class="ic_chapter_icon">
             </div>
-            <p class="chapter-title">XI. Community Tuberculosis Control</p>
+            <p class="chapter-title">XI. Community Tuberculosis Prevention Control </p>
         </div>
         <p class="last-updated"><i>Last Updated October 2025</i></p>
     </div>

diff --git a/...ommunity_tuberculosis_control__c__tb_case_definitions_for_public_health_surveillance.html b/...ommunity_tuberculosis_control__c__tb_case_definitions_for_public_health_surveillance.html
@@ -20,7 +20,7 @@
                 <div>
                     <img src="../assets/ic_chapter.svg" width="16" height="16" class="ic_chapter_icon">
                 </div>
-                <p class="chapter-title">XI. Community Tuberculosis Control</p>
+                <p class="chapter-title">XI. Community Tuberculosis Prevention Control </p>
             </div>
             <p class="last-updated"><i>Last Updated October 2025</i></p>
         </div>
@@ -55,10 +55,14 @@
         <ul>
             <li> <b>Confirmed</b> A case that meets the clinical case definition or is laboratory confirmed</li>
             <li>A case should not be counted twice within any consecutive 12-month period. However, a case occurring in a patient who previously had verified TB disease should be reported and counted again if more than 12 months have elapsed since the patient completed therapy. A case should also be reported and counted again if the patient was lost to supervision for greater than 12 months and TB disease can be verified again. Mycobacterial diseases other than those caused by M. tuberculosis complex should not be counted in tuberculosis morbidity statistics unless there is concurrent tuberculosis.</li>
-            <li>*Use of rapid identification techniques for M. tuberculosis (e.g., DNA probes and mycolic acid high-pressure liquid chromatography performed on a culture from a clinical specimen) are acceptable under this criterion.</li>
-            <li>**Nucleic acid amplification (NAA) tests must be accompanied by culture for mycobacteria species for clinical purposes. A culture isolate of M. tuberculosis complex is required for complete drug susceptibility testing and also genotyping. However, for surveillance purposes, CDC will accept results obtained from NAA tests approved by the Food and Drug Administration (FDA) and used according to the approved product labeling on the package insert, or a test produced and validated in accordance with applicable FDA and Clinical Laboratory Improvement Amendments (CLIA) regulations.</li>
         </ul>
     </div>
+    <p>
+        *Use of rapid identification techniques for M. tuberculosis (e.g., DNA probes and mycolic acid high-pressure liquid chromatography performed on a culture from a clinical specimen) are acceptable under this criterion.
+    </p>
+    <p>
+     **Nucleic acid amplification (NAA) tests must be accompanied by culture for mycobacteria species for clinical purposes. A culture isolate of M. tuberculosis complex is required for complete drug susceptibility testing and also genotyping. However, for surveillance purposes, CDC will accept results obtained from NAA tests approved by the Food and Drug Administration (FDA) and used according to the approved product labeling on the package insert, or a test produced and validated in accordance with applicable FDA and Clinical Laboratory Improvement Amendments (CLIA) regulations.
+    </p>
 </div>
 
 </body>

diff --git a/...ain/assets/pages/11_community_tuberculosis_control__d__role_of_the_health_department.html b/...ain/assets/pages/11_community_tuberculosis_control__d__role_of_the_health_department.html
@@ -20,7 +20,7 @@
                 <div>
                     <img src="../assets/ic_chapter.svg" width="16" height="16" class="ic_chapter_icon">
                 </div>
-                <p class="chapter-title">XI. Community Tuberculosis Control</p>
+                <p class="chapter-title">XI. Community Tuberculosis Prevention Control </p>
             </div>
             <p class="last-updated"><i>Last Updated October 2025</i></p>
         </div>

diff --git a/...sis_control__e__hospital_discharge_planning_for_patients_with_suspected_or_proven_tb.html b/...sis_control__e__hospital_discharge_planning_for_patients_with_suspected_or_proven_tb.html
@@ -20,7 +20,7 @@
                 <div>
                     <img src="../assets/ic_chapter.svg" width="16" height="16" class="ic_chapter_icon">
                 </div>
-                <p class="chapter-title">XI. Community Tuberculosis Control</p>
+                <p class="chapter-title">XI. Community Tuberculosis Prevention Control </p>
             </div>
             <p class="last-updated"><i>Last Updated October 2025</i></p>
         </div>

diff --git a/...pages/11_community_tuberculosis_control__f__interjurisdictional_tb_notification(ijn).html b/...pages/11_community_tuberculosis_control__f__interjurisdictional_tb_notification(ijn).html
@@ -21,7 +21,7 @@
                 <div>
                     <img src="../assets/ic_chapter.svg" width="16" height="16" class="ic_chapter_icon">
                 </div>
-                <p class="chapter-title">XI. Community Tuberculosis Control</p>
+                <p class="chapter-title">XI. Community Tuberculosis Prevention Control </p>
             </div>
             <p class="last-updated"><i>Last Updated October 2025</i></p>
         </div>

diff --git a/...1_community_tuberculosis_control__g__curetb_program_(internation_linkage_to_tb_care).html b/...1_community_tuberculosis_control__g__curetb_program_(internation_linkage_to_tb_care).html
@@ -20,7 +20,7 @@
                 <div>
                     <img src="../assets/ic_chapter.svg" width="16" height="16" class="ic_chapter_icon">
                 </div>
-                <p class="chapter-title">XI. Community Tuberculosis Control</p>
+                <p class="chapter-title">XI. Community Tuberculosis Prevention Control </p>
             </div>
             <p class="last-updated"><i>Last Updated October 2025</i></p>
         </div>

diff --git a/...main/assets/pages/12_alternative_housing_program_for_homeless_tb_patients_in_georgia.html b/...main/assets/pages/12_alternative_housing_program_for_homeless_tb_patients_in_georgia.html
@@ -20,7 +20,7 @@
                 <div>
                     <img src="../assets/ic_chapter.svg" width="16" height="16" class="ic_chapter_icon">
                 </div>
-                <p class="chapter-title">XII. Alternative Housing Program for Homeless TB Patients in Georgia</p>
+                <p class="chapter-title">XII. Alternative Housing Program for Persons with TB Experiencing Homelessness in Georgia </p>
             </div>
             <p class="last-updated"><i>Last Updated October 2025</i></p>
         </div>

diff --git a/app/src/main/assets/pages/1_epidemiology.html b/app/src/main/assets/pages/1_epidemiology.html
@@ -67,7 +67,7 @@
         </p>
 
         <img src="../assets/chapter_1_image_1.png" />
-        <span class="uk-text-small">Source: CDC</span>
+        <span class="uk-text-small">Source: CDC <a href="https://www.cdc.gov/tb-surveillance-report-2023/summary/national.html">https://www.cdc.gov/tb-surveillance-report-2023/summary/national.html</a></span>
 
         <!-- <p class="uk-paragraph">In the U.S., there was a resurgence of TB from 1985 to 1992. The number of cases increased 20% during this time period, peaking in 1992 with 26,673 cases reported. The increased case numbers were attributed to the HIV epidemic, decreased funding for public health, immigration from countries where TB is endemic, and transmission of TB in congregate settings such as hospitals, correctional institutions, and homeless shelters.
         </p> -->
@@ -92,7 +92,7 @@
         </p>
 
         <img src="../assets/chapter_1_image_2.png" />
-        <span class="uk-text-small">Source: CDC</span>
+        <span class="uk-text-small">Source: CDC <a href="https://www.cdc.gov/tb-surveillance-report-2023/summary/national.html">https://www.cdc.gov/tb-surveillance-report-2023/summary/national.html</a></span>
 
         <p class="uk-paragraph">
           TB is not evenly distributed among the U.S. population. Recovery from

diff --git a/app/src/main/assets/pages/2_diagnostic_tests_for_latent_tb_infection_(ltbi).html b/app/src/main/assets/pages/2_diagnostic_tests_for_latent_tb_infection_(ltbi).html
@@ -27,7 +27,7 @@
         <hr>
     </div>
     <p class="uk-paragraph">There is no "gold standard" test for latent TB infection (LTBI).
-        Two types of diagnostic tests to detect LTBI are now available.
+        Two types of diagnostic tests to detect LTBI are commercially available.
         These include the tuberculin skin test (TST) which has been available for > 100 years and a newer generation of
         diagnostic tests, the interferon-γ release assays (IGRAs), which are T-cell-based in
         - vitro blood tests. Two IGRAs are approved for use by the U.S.